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Abstract 15 
Neonatal infection with Streptococcus agalactiae (Group B streptococcus – GBS) is a life 16 
threatening condition which is preventable if colonised mothers are identified and given 17 
antibiotic prophylaxis during labour. Conventional culture is time consuming and unreliable, 18 
and many available non-culture diagnostics are too complex to implement routinely at point 19 
of care. Loop-mediated isothermal amplification (LAMP) is a method which enables the 20 
rapid and specific detection of target nucleic acid sequences in clinical material without any 21 
requirements for extensive sample preparation. A prototype LAMP assay targeting the GBS 22 
sip gene is described. The assay was 100% specific for GBS with a Limit of Detection of 14 23 
genome copies per reaction. The clinical utility of the prototype LAMP assay for rapid direct 24 
molecular detection of GBS was determined by testing a total of 157 vaginal swabs with 25 
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minimal sample processing using a rapid lysis solution. Compared to a reference qPCR assay 26 
the direct LAMP protocol had a sensitivity and specificity of 95.4% and 100% with a Positive 27 
Predictive Value (PPV) and Negative Predictive Value (NPV) of 100% and 98.3%. Positive 28 
(LR+) and negative (LR-) likelihood ratios were infinity and 0.05 respectively.  The direct 29 
LAMP method took a mean of 45 minutes from receipt of a swab to generation of confirmed 30 
result compared to 2 hours 30 minutes for the reference qPCR test. The direct LAMP 31 
protocol described is easy to perform facilitating rapid and accurate detection of GBS in 32 
vaginal swabs. This test has potential for use at point of care.  33 
 34 
Introduction 35 
Streptococcus agalactiae (Group B streptococcus - GBS) is the leading cause of early onset 36 
neonatal sepsis [1-5]. Asymptomatic GBS colonisation of the vagina and lower 37 
gastrointestinal tract occurs in 10-30% of pregnant women and is the most significant risk 38 
factor for neonatal GBS disease as transmission can occur from the recto/vaginal area during 39 
childbirth [4,6-9]. The implementation of culture based antepartum screening programmes for 40 
all pregnant women at 34-38 weeks and initiating intrapartum antibiotic prophylaxis has 41 
helped to reduce but not eliminate neonatal early onset disease (EOD) in many industrialised 42 
countries [4,10,11]. Despite technological advances the primary method for detection of GBS 43 
colonisation remains selective laboratory based culture of vaginal and/or rectal swab 44 
specimens followed by ancillary confirmation tests. This approach demonstrates variable 45 
sensitivity [12-14] and is associated with long turnaround times of 18-72 hours rendering 46 
culture unfeasible as an intrapartum test. Thus, women who give birth prematurely are not 47 
screened, and women who become colonised after screening are not identified [7,8]. A 48 
sensitive screening assay which could rapidly determine GBS status during labour would be 49 
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beneficial as it would facilitate targeted therapy whilst reducing the risks associated with 50 
antibiotic use in non-colonised women [15].  51 
Quantitative Polymerase Chain Reaction (qPCR) assays can provide test results in a few 52 
hours [15-20]. However, requirements for expensive equipment, intricate sample preparation, 53 
skilled staff and/or support precludes the use of PCR at point of care (POC) [21-23].  54 
Loop-mediated isothermal amplification (LAMP) is an isothermal molecular amplification 55 
technique which offers simple qualitative detection combined with exceptional sensitivity and 56 
specificity [24-26]. The single reaction temperature (60 – 650C) employed by LAMP means 57 
there are no requirements for thermocycling resulting in a need for less complex equipment 58 
making it amenable to use at POC [22,27]. Furthermore compared to PCR, LAMP is also 59 
demonstrably more resistant to inhibitors found in clinical material indicating potential for 60 
direct application to clinical specimens and/or crude sample preparations [21,28,29]. This is 61 
advantageous as one of the issues frequently hampering application of Nucleic acid 62 
amplification tests (NAAT) at POC are requirements to perform dedicated  multistep nucleic 63 
acid extraction steps which add to test complexity, cost and turnaround time [21-23]. Whilst a 64 
number of  LAMP assays for GBS detection have been developed previously, they are not 65 
amenable for POC use having requirements for an 18-24 hr pre-enrichment culture step [20], 66 
require multiple time consuming manipulations prone to contamination [30] or have 67 
unproven clinical efficacy [31,32].  68 
Here we describe a newly designed GBS LAMP assay targeting S. agalactiae sip gene. As a 69 
proof of concept the LAMP assay was applied to residual vaginal swabs which had 70 
undergone minimal sample processing (Direct detection – no extraction protocol) with a rapid 71 
lysis solution containing the bacteriolytic enzyme achromopeptidase (ACH). ACH 72 
demonstrates high lytic activity against a range of gram positive cocci including GBS [23,33-73 
35].  74 
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Materials and Methods 75 
 76 
Clinical Specimens: The study was approved by the Office for Research Ethics committee 77 
Northern Ireland (reference 09/NIR02/43). A total of 157 residual vaginal swabs from 78 
pregnant women submitted to Department of Microbiology, Belfast Health and Social Care 79 
Trust (BHSCT) for bacterial investigations between March – July 2013 were 80 
opportunistically collected and utilised for the clinical validation study. The sample set 81 
consisted of 153 High Vaginal swabs (HVS) and 4 Low Vaginal Swabs (LVS). All vaginal 82 
swabs were collected on plastic rayon tipped swabs (Sterilin Ltd., Newport, UK) and 83 
transported to laboratory in AMIES transport medium. Culture of all swab specimens was 84 
carried out according to BHSCT Standard Operating Procedure by laboratory staff unaware 85 
that the samples were to be subsequently included in a study. Briefly, each swab was plated 86 
onto Columbia Blood agar (CBA) and differential Granada™ agar (bioMérieux, Basingstoke, 87 
UK).  CBA plates were incubated in 10% CO2 atmosphere with Granada™ plates incubated 88 
anaerobically at 370C. Plates were examined at 18-24 hours and again at 48 hours with 89 
presumptive positive GBS colonies on Granada™ agar identified by production of orange 90 
pigment. Presumptive GBS colonies on CBA were identified on the basis of haemolysis. All 91 
suspect colonies were appropriately identified by a combination of standard tests including 92 
Gram stain, catalase activity and latex agglutination using SLIDEX® Strepto Plus kit 93 
(bioMérieux, Basingstoke, UK) to identify the presence of Group B antigen. Following 94 
routine bacteriological culture all residual swabs were stored at +40C for a maximum of one 95 
week until required for processing and molecular analysis. 96 
 97 
Rapid Sample preparation method for direct LAMP: Lysis solution consisted of 10 U/L of 98 
achromopeptidase (ACH) (Sigma-Aldrich, Dorset, UK) in 10 mmol/L Tris-HCL pH8.0, 1 99 
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mmol/L EDTA (Sigma-Aldrich, Dorset, UK). Residual swab specimens were removed from 100 
AMIES transport medium tubes with ~2 cm end physically broken off into 400 µl pre 101 
aliquoted lysis solution [ACH] by firmly pressing the swab against the side of a microfuge 102 
tube (Sarstedt, Leicester, UK). Tubes were capped and swabs incubated at ambient ‘room 103 
temperature’ (22 - 240C) for 5 minutes before boiling at 950C for 5 minutes in a dedicated 104 
heat block to simultaneously deactivate ACH and denature any target DNA for LAMP 105 
analysis. Samples were immediately cooled by placing directly on ice. A 5µl aliquot of lysis 106 
supernatant was used for GBS direct LAMP testing as outlined below. Remaining lysis 107 
supernatant was stored at 40C. 108 
 109 
Nucleic acid (NA) extraction for qPCR and indirect LAMP: GBS reference and clinical 110 
isolates were pre-treated with ACH before undergoing total nucleic acid extraction using 111 
QIAamp blood DNA mini extraction kit (Qiagen, Crawley, UK). A 200 µl saline suspension 112 
of each GBS isolate was prepared and added to an equal volume of ACH 20 U/L for a final 113 
working concentration of ACH of 10 U/L. The suspension was incubated at room 114 
temperature for 5 minutes before being boiled at 950C/5 minutes. 200 µl aliquot of each 115 
lysate was then added to AL lysis buffer (Qiagen, Crawley, UK) and processed as per 116 
manufacturer’s instructions to produce 100 µl of genomic extract.  117 
Bacterial and fungal genomic DNA for specificity evaluation was obtained using QIAamp 118 
blood DNA mini extraction kit (Qiagen, Crawley, UK). 200 µl saline suspensions of each 119 
target organism were added to AL lysis buffer and processed as per manufacturer’s 120 
instructions to produce 100 µl of genomic extract.  121 
Vaginal swab lysates were extracted as follows; A 200 µl aliquot of ACH lysis supernatant 122 
(produced as indicated in previous section) was removed from each clinical swab specimen 123 
and extracted using MagNA Pure 96 viral NA small volume kit and MagNA Pure instrument 124 
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(Roche Diagnostics, Mannheim, Germany) as per manufacturer’s instructions. Resultant 100 125 
µl genomic extract aliquots were stored at -800C until required for qPCR and LAMP 126 
(indirect) analysis. 127 
 128 
LAMP primers and reaction: LAMP primers targeting a highly conserved region of S. 129 
agalactiae sip gene (HiberGene Diagnostics, Ireland) were employed throughout. The LAMP 130 
primer set consisted of forward (sip_FIP) and reverse (sip_BIP) ‘inner’ primers, forward 131 
(sip_F3) and reverse (sip_B3) ‘outer’ primers and forward (sip_FL) and reverse (sip_BL) 132 
‘loop’ primers. Optimised GBS LAMP consisted of 5 µl of template DNA, 12.5 µl of LAMP 133 
isothermal Master Mix ISO 001 (OptiGene Ltd., Horsham, UK) containing novel strand 134 
displacing DNA polymerase (GspSSD), propriety thermostable inorganic pyrophosphatase, 135 
reaction buffer, MgCl, dNTP’s, DNA intercalating dye, 2 µM each of FIP and BIP, 0.2 µM 136 
each of F3 and B3, 1 µM each of FL and BL and Nuclease Free Water (Promega, 137 
Southampton, UK) for a final reaction volume of 25 µl. The GENIE® II (OptiGene Ltd, 138 
Horsham, UK) real time fluorometer was utilised for concurrent target isothermal 139 
amplification and detection. LAMP reactions were performed at a previously identified 140 
optimal reaction temperature of 620C for 30 minutes followed by a heating and cooling step 141 
to 98–80 0C (0.05 0C/s) which allows re-annealing of amplified DNA and display of a 142 
specific annealing curve. Positive and negative controls were included for each run and 143 
stringent precautions undertaken to prevent cross contamination. Positive LAMP reactions 144 
were identified by GENIE® II (OptiGene Ltd, Horsham, UK) instrument software. In the 145 
results section each positive reaction had a Time to positivity (TT) value in minutes and 146 
seconds and a specific melting point temperature (Tm) in degrees centigrade (0C). 147 
 148 
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Real Time PCR (qPCR): qPCR was employed as the reference molecular detection method. 149 
Primer and hybridisation probe sequences targeting S. agalactiae sip gene were as previously 150 
described [17]. Primer sequences as follows: Forward primer 5’–151 
ATCCTGAGACAACACTGACA–3’, and reverse primer 5’- 152 
TTGCTGGTGTTTCTATTTTCA-3’. The hybridisation probe 5’- 153 
ATCAGAAGAGTCATACTGCCACTTC3’ contained a FAM label on 5’ end with a Black 154 
Hole Quencher 1 (BHQ1) on 3’ end. Primers and hybridisation probe were synthesised by 155 
Eurogentec (Eurogentec, Liège Belgium). The final qPCR reaction mix contained 1X 156 
Platinum® UDG Mastermix (Life Sciences, Paisley, UK), 0.2 µM Bovine serum albumin 157 
(Sigma, Dorset, UK), total of 4 mmol/L MgCl2, 0.4 µM forward and reverse primers, 0.2 µM 158 
hybridisation probe, Nuclease Free Water (Promega, Southampton, UK) and 3 µl of target 159 
template for a final reaction volume of 12 µl. qPCR was performed using a Light Cycler 480 160 
(LC480) instrument (Roche Diagnostics, Mannheim, Germany). A No Template Control 161 
(NTC) consisting of Nuclease Free Water (Promega, Southampton, UK) and a plasmid 162 
reference standard containing 3.50E06 sip genome copies per ml were included for all qPCR 163 
runs. The qPCR run parameters consisted of an initial step of 95°C for 10 minutes followed 164 
by an amplification program for 45 cycles of 10 seconds at 95°C, 30 seconds at 60°C, 1 165 
second at 72°C with fluorescence acquisition at the end of each extension. Data was analysed 166 
using LC480 software and GBS genome copy number for positive specimens determined 167 
from crossing point threshold (Cp) relative to an external positive control curve. 168 
 169 
Specificity & sensitivity: Specificity of GBS LAMP was evaluated using total genomic 170 
extracts (containing approximately 10E07 genome copies) derived from a range of bacteria 171 
(n=55) and fungi (n=1). These included a number of GBS reference, clinical and veterinary 172 
isolates (n=17). Reaction mix without DNA template was included as a negative control. 173 
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The following organisms were tested; Streptococcus agalactiae (NCTC 11360, NCTC 8187, 174 
NCTC 11078, NCTC 11079, NCTC 11080, NCTC 11930, NCTC 9829, ATCC 12386, ID: 175 
603532, ID: 603535, ID: 605872, RVH2419/12, RVH2543/12, RVH60/13, RVH524/13, 176 
VSD04988, VSD04946), Streptococcus pneumoniae (ATCC 49619, RVH59/07), 177 
Streptococcus parasanquis (RVH74/07), Streptococcus intermedius (RVH305/07), 178 
Streptococcus pyogenes (ATCC 19615), Streptococcus salivarius (RVH557/13), 179 
Streptococcus vestibularis (RVH527/13), Streptococcus mitis/oralis (RVH508/13), 180 
Streptococcus dysglactiae (RVH497/13), Streptococcus anginosus (RVH452/13), 181 
Staphylococcus aureus (ATCC 25923), MRSA (NCTC 10442), Staphylococcus epidermidis 182 
(ATCC 12228), Staphylococcus lugdunensis (RVH isolate), Staphylococcus capitis (RVH 183 
isolate), Enterococcus faecalis (ATCC 29212, RVH009/07), Micrococcus luteus 184 
(RVH290/07), Brevibacillus brevi (RVH381/13), Bacillus cereus (RVH299/13), Neisseria 185 
meningitidis (NCTC 10791 serogroup Y, RVH531/07 serogroup B), Neisseria sicca 186 
(RVH920/06), Klebsiella pneumoniae (RVH45/07), Klebsiella oxytoca (RVH135/07), 187 
Enterobacter aerogenes (NCTC 10006, RVH001/07), Enterobacter cloacae (NCTC 9394), 188 
Serratia marcescens (RVH287/07), Acinetobacter baumanii (RVH36/07), Acinetobacter 189 
lwoffii (RVH98/07), Escherichia coli (NCTC 9001, ATCC 25922), Citrobacter freundii 190 
(NCTC 9750), Haemophilius influenzae (NCTC 4560), Sphingobacterium spiritivorum 191 
(ATCC 33861), Stenotrophomonas maltophilia (ATCC 17666), Pseudomonas aeruginosa 192 
(ATCC 27853), Gardnerella vaginalis (ATCC 49145), Candida albicans (ATCC 10028). 193 
LAMP analytical sensitivity (limit of detection - LOD) was determined using tenfold serial 194 
dilutions of S. agalactiae ATCC 12386 nucleic acid extracts analysed in duplicate containing 195 
2.8E07 to 2.8E02 genome copies per ml respectively. A No Template Control (NTC) 196 
consisting of Nuclease Free Water (Promega, Southampton, UK) was included with all 197 
LAMP runs. 198 
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Statistical analysis: For purposes of validation the reference molecular method was defined 199 
as achromopeptidase (ACH) pre-treatment of a clinical swab specimen followed by Nucleic 200 
Acid (NA) extraction and qPCR testing. A specimen was considered a true positive if: (i) 201 
GBS was obtained following culture; or (ii) Specimen was identified as GBS qPCR positive. 202 
All qPCR and LAMP results were compared with routine culture results. Sensitivity, 203 
specificity, positive predictive value (PPV), negative predictive values (NPV), positive (LR+) 204 
and negative (LR-) likelihood ratios for each test method were calculated. The level of 205 
agreement between LAMP and qPCR assays was assessed using Kappa (κ) coefficient with 206 
95% confidence levels.  κ was calculated using the formula Pr(o) - Pr(e)/1 - Pr(e), where  207 
Pr(o) is the observed agreement and Pr(e) is the hypothetical probability of chance 208 
agreement.  209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
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Results 224 
 225 
Analytical reactivity, specificity and sensitivity: The LAMP assay successfully amplified 226 
DNA from all GBS reference, clinical and veterinary strains analysed with Time to positivity 227 
(TT) values of less than 20 minutes and specific melt point temperature values (Tm) ranging 228 
from 85.5 – 86.210C obtained. No amplification was recorded for any other bacterial or 229 
fungal species tested. This confirmed 100% specificity of the GBS LAMP assay.  230 
Employing tenfold serial dilutions of a known concentration (2.8E07 to 2.8E02 copies per 231 
ml) of GBS ATCC 12386 nucleic acid extracts in duplicate the LAMP assay consistently 232 
detected 2.80E03 sip genome copies per ml corresponding to an analytical Limit of Detection 233 
(LOD) of 14 genome copies per reaction (for 5µl input volume and final reaction volume of 234 
25µl). The mean GBS LAMP TT and Tm for 2.80E03 sip genome copies per ml were 235 
determined as 11 minutes and 85.980C respectively. The LAMP LOD was slightly higher 236 
than that achieved for qPCR which in our laboratory had a previously determined LOD of 237 
1.00E03 genome copies per ml equating to 2 genome copies per reaction. 238 
 239 
Clinical Validation: Routine bacteriological culture was compared to the reference qPCR 240 
molecular method, direct LAMP and indirect LAMP methods. Summary of findings are 241 
outlined in Tables 1 and 2. A total of 36/157 (22.9%) specimens analysed were confirmed as 242 
GBS culture positive. All 36 culture positive GBS specimens were correctly identified as 243 
positive by qPCR and by the direct and indirect LAMP methods. An additional 7 specimens 244 
were identified as GBS positive by qPCR giving a total of 43/157 (27.4%)  ‘true’ positive 245 
specimens. Comparison of difference between qPCR and culture results was statistically 246 
significant (p=0.0005). The loads of GBS determined by qPCR (genome copies per ml) for 247 
positive clinical specimens were as follows: Mean = 1.23E+08; Max= 2.50E+09; Min= 248 
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1.90E+03; Median= 2.40E+06. Compared to culture qPCR had a sensitivity and specificity of 249 
100% and 94.2% with a PPV and NPV of 83.7% and 100%.  Positive (LR+) and negative 250 
(LR-) likelihood ratios were infinity and 0.16 respectively. The mean genome copies per ml 251 
of the seven identified specimens missed by culture but positive by qPCR was 1.09E06 252 
(Range 1.90E03 – 7.60E06; Median 5.50E03) compared to 1.47E08 (Range 4.60E03 - 253 
2.50E09; Median 3.65E06) for specimens identified as both culture and qPCR positive. This 254 
difference in mean genome copies per ml was statistically significant (p=<0.0001). 255 
The direct LAMP method took a mean of 45 minutes from receipt of a swab to generation of 256 
confirmed result compared to 1 hour 45 minutes for indirect LAMP (extraction protocol) and 257 
2 hours 30 minutes for reference qPCR test. 258 
There was a very high level of agreement between LAMP (Indirect and direct) methods and 259 
reference qPCR assay. Compared to qPCR agreement ranged from 100% for indirect LAMP 260 
(Κappa = 1.0; Strength of agreement = perfect) to a level of agreement of 98.7% for direct 261 
LAMP (Kappa = 0.968; Strength of agreement = very good). Indirect LAMP method 262 
identified 43/157 (27.4%) specimen extracts as GBS positive with the direct LAMP method 263 
identifying a total of 41/157 (26.1%) of crude specimen ACH lysates as GBS positive. 264 
Compared to qPCR the indirect LAMP method had a sensitivity and specificity of 100% and 265 
a PPV and NPV of 100%. Positive (LR+) and negative (LR-) likelihood ratios were infinity 266 
and 0.00 respectively. Compared to qPCR the direct LAMP had a sensitivity and specificity 267 
of 95.4% and 100% with a PPV and NPV of 100% and 98.3%. Positive (LR+) and negative 268 
(LR-) likelihood ratios were infinity and 0.05 respectively. Two specimens (405 & 453 see 269 
Table 2) were identified as false negative after analysis by direct LAMP method. Following 270 
nucleic acid extraction and analysis by qPCR these specimens tested GBS positive with 271 
genome copy loads of 1.90E+03 per ml (9.5 copies per 5µl addition) and 1.91+E03 per ml 272 
(9.6 copies per 5µl addition) respectively. Additionally following nucleic acid extraction both 273 
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of the specimens tested LAMP positive returning TT values of 12.15 and 29.00 minutes 274 
respectively. Overall the mean time to achieve positivity (TT) for direct LAMP method was 275 
higher compared to indirect LAMP method; 14.83 minutes (range 8.15 – 26.00 minutes) 276 
compared to 9.60 minutes (range 5.00 – 29.00 minutes). Testing performance comparison is 277 
displayed in Table 1 with all specimens identified as positive by either culture, qPCR and/or 278 
LAMP is presented in Table 2. 279 
 280 
 281 
Discussion 282 
Screening for maternal GBS colonisation at 35-37 weeks via selective culture is a time 283 
consuming and inadequate method which fails to identify all cases of GBS [12,13,20]. There 284 
is a recognised clinical need for rapid, highly sensitive and specific methods to detect GBS 285 
which can be used at POC before or during labour to identify women for prophylactic 286 
antibiotic treatment. Currently qPCR offers the required specification to achieve these goals 287 
however technical obstacles including requirements for stringent sample preparation, 288 
complex instrumentation and skilled personnel have restricted their introduction at POC [21- 289 
23]. The robust chemistry, ease of operation, rapidity, low cost, and modest equipment 290 
requirements associated with LAMP represent significant advantages over existing molecular 291 
methods for detection of pathogens [22,27,29,36]. 292 
The primary objective of this proof of concept study was to validate the effectiveness of a 293 
prototype LAMP assay (HiberGene diagnostics, Ireland) in combination with a simple rapid 294 
specimen lysis protocol (without extraction) for direct detection of GBS in residual vaginal 295 
swabs. Pre-lysis with ACH at a concentration of 10 U/L for 5 minutes at room temperature 296 
has been previously shown in our laboratory to be a highly effective method to significantly 297 
increase the available yield of GBS nucleic acid for molecular analysis [35]. Eliminating the 298 
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requirement for nucleic acid extraction not only simplified the test procedure but also resulted 299 
in significant time savings with direct LAMP taking 45 minutes from receipt of swab to 300 
definitive GBS result compared to 60 minutes and >2 hrs for indirect LAMP and qPCR 301 
respectively. The GBS LAMP assay had an analytical LOD of 2.80E03 genome copies per ml 302 
which compared favourably with the determined reference qPCR analytical LOD of 1.00E03 303 
genome copies per ml. Crucially when applied to clinical specimens, qPCR and both direct 304 
and indirect LAMP methods resulted in identification of additional GBS positives (n=7) 305 
missed by culture. These findings were not unexpected and are consistent with previous 306 
studies demonstrating an increase in GBS positivity rate when Nucleic acid amplification 307 
tests (NAAT’s) are directly compared to culture [13,16,18,19,20]. Higher detection rates of 308 
NAAT’s have been claimed to be due to the inability of culture to detect low numbers of 309 
GBS bacteria but may also be attributed to the presence of antagonistic flora and/or the 310 
detection of non-culturable cells [19,37].  311 
Compared to the reference qPCR method the direct LAMP had a sensitivity of 95.4% and 312 
specificity of 100%. High specificity is an intrinsic feature of LAMP and reflects the 313 
presence of six specific LAMP primers recognising eight target regions on sip gene. The 314 
direct LAMP assay returned higher mean TT values for identified positive specimens 315 
compared to the indirect LAMP assay applied to the same samples which had undergone 316 
nucleic acid extraction (14.69 minutes versus 9.61 minutes respectively - difference of 5.08 317 
minutes). Additionally the direct LAMP assay failed to detect GBS in two specimens 318 
subsequently shown to contain low genomic loads by qPCR. These findings indicate that the 319 
presence of component(s) in crude lysate matrices can impede LAMP and in conjunction 320 
with low initial GBS loads may have contributed to the two false negative results. Solution(s) 321 
to combat this could include prior centrifugation and/or a dilution step(s) although this would 322 
complicate the assay protocol and make application less attractive at POC. At present the 323 
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clinical significance of specimens containing a low GBS burden remains to be determined 324 
[16]. The excellent performance of qPCR and LAMP in this study must also be taken in 325 
context as ‘second hand’ residual vaginal swabs post bacteriological culture as described 326 
would certainly benefit from further field evaluation employing dedicated recto/vaginal 327 
swabs in order to fully establish diagnostic and analytical characteristics. Efforts are currently 328 
underway to address this. 329 
Whilst this study utilised a GENIE® II fluorometer (cost £5000) to conduct isothermal 330 
amplification and specific detection of GBS in real time it would be entirely feasible to 331 
perform GBS LAMP testing using a simple heating block in conjunction with simple visual 332 
endpoint interpretation. This represents a commonly applied and valid approach for LAMP 333 
testing particularly in resource limited settings [27,38,39].  334 
In conclusion the data presented demonstrates the efficacy of employing LAMP on minimally 335 
processed vaginal swabs for rapid direct molecular detection of GBS. The simplicity of the 336 
direct LAMP protocol combined with described sensitivity and specificity are desirable 337 
characteristics amenable to POC use in resource limited settings.  338 
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Table 1 LAMP (Indirect & direct) and culture testing performance for clinical swabs (n=157) 495 
compared to reference GBS qPCR method. For LAMP the mean, maximum, minimum and 496 
median time to achieve LAMP positivity in minutes: seconds (TT) and specific melt 497 
temperatures (Tm) in degrees centigrade are shown. 498 
GBS qPCR 
 
LAMP (INDIRECT) LAMP (DIRECT) Culture 
Positive Negative Positive Negative Positive Negative 
Positive 43 0 41 2 36 7 
Negative 0 114 0 114 0 114 
Sensitivity 100% 95.4% 100% 
Specificity 100% 100% 94.2% 
PPV 100% 100% 83.7% 
NPV 100% 98.3% 100% 
(LR+) Infinity Infinity Infinity 
(LR-) 0.00 0.05 0.16 
Mean TT  (Tm) 09.61 mins (86.660C) 14.69 mins (86.680C) NA 
Max TT  (Tm) 29.00 mins (87.600C) 26.00 mins (87.600C) NA 
Min TT  (Tm) 05.00 mins (85.860C) 08.15 mins (85.750C) NA 
Median TT  (Tm) 08.30 mins (86.390C) 14.00 mins (86.400C) NA 
NA; Not applicable  499 
 500 
Table 2 Individual vaginal swab specimens identified either as GBS positive by culture, 501 
qPCR, indirect and/or direct LAMP methods. For qPCR genome copies per ml detected are 502 
shown. For LAMP the time to achieve positivity in minutes TT and specific melt temperatures 503 
(Tm) in degrees centigrade are shown 504 
Specimen 
Code 
Culture 
Result 
qPCR 
Result 
copies/ml 
Indirect LAMP 
Result TT mins 
(Tm) 
Direct LAMP 
Result TT mins 
(Tm) 
334 + + 2.4E06 + 08.20 (87.200C) + 17.50 (87.600C) 
337 + + 5.6E03 + 11.50 (87.600C) + 22.20 (87.600C) 
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354 + + 1.1E09 + 05.30 (87.300C) + 09.51 (87.400C) 
355 - + 4.2E03 + 10.30 (87.110C) + 21.00 (87.100C) 
370 + + 9.0E04 + 09.30 (87.600C) + 19.00 (87.250C) 
372 - + 6.3E03 + 15.15 (87.410C) + 16.00 (86.000C) 
373 + + 2.2E06 + 08.00 (87.100C) + 14.50 (87.100C) 
374 + + 2.5E09 + 05.00 (87.300C) + 09.30 (87.410C) 
376 + + 3.6E04 + 09.30 (87.430C) + 20.15 (87.600C) 
380 + + 2.8E04 + 12.00 (87.090C) + 24.15 (87.200C) 
382 + + 4.6E03 + 17.15 (87.550C) + 21.00 (87.400C) 
392 - + 5.5E03 + 12.00 (87.400C) + 14.50 (86.610C) 
395 + + 2.4E04 + 11.45 (87.350C) + 20.30 (87.550C) 
403 + + 1.1E04 + 09.45 (86.040C) + 22.45 (87.380C) 
405 - + 1.9E03 + 12.15 (86.120C) - 
408 + + 1.7E05 + 09.00 (86.090C) + 26.00 (87.440C) 
425 + + 5.6E07 + 07.00 (85.860C) + 08.45 (85.750C) 
426 - + 3.7E04 + 12.15 (86.140C) + 15.45 (86.120C) 
427 + + 2.8E06 + 08.30 (86.110C) + 11.30 (85.920C) 
446 + + 1.5E08 + 08.00 (87.000C) + 17.45 (87.110C) 
448 - + 7.6E06 + 09.45 (86.910C) + 20.00 (87.020C) 
451 + + 1.3E08 + 07.15 (87.000C) + 15.45 (87.210C) 
453 - + 1.9E03 + 29.00 (87.140C) - 
685 + + 2.2E08 + 07.00 (86.300C) + 12.30 (86.500C) 
687 + + 1.0E08 + 07.20 (86.300C) + 11.00 (86.510C) 
695 + + 9.0E04 + 11.15 (86.490C) + 17.45 (86.390C) 
711 + + 1.1E08 + 06.50 (86.200C) + 10.30 (86.380C) 
729 + + 5.6E07 + 07.21 (86.200C) + 13.15 (86.430C) 
732 + + 2.6E04 + 11.50 (86.500C) + 18.15 (86.400C) 
736 + + 9.4E05 + 08.00 (86.300C) + 11.30 (86.300C) 
755 + + 5.2E07 + 07.00 (86.280C) + 10.45 (86.400C) 
782 + + 2.4E06 + 08.45 (86.490C) + 11.10 (86.300C) 
789 + + 1.6E04 + 17.00 (86.390C) + 19.00 (86.200C) 
793 + + 2.3E07 + 08.00 (86.490C) + 11.00 (86.400C) 
825 + + 4.5E06 + 08.15 (86.290C) + 10.45 (86.260C) 
826 + + 1.1E07 + 08.30 (86.290C) + 09.45 (86.300C) 
831 + + 9.3E07 + 06.45 (86.390C) + 09.00 (86.400C) 
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843 + + 4.2E08 + 06.15 (86.290C) + 08.15 (86.360C) 
864 + + 2.0E08 + 06.30 (86.290C) + 08.15 (86.330C) 
870 + + 7.0E05 + 09.30 (86.390C) + 14.00 (85.800C) 
872 + + 8.5E06 + 08.00 (86.000C) + 10.15 (85.800C) 
876 + + 5.2E07 + 07.15 (86.290C) + 11.00 (86.420C) 
891 + + 1.8E06 + 08.30 (86.290C) + 11.00 (86.390C) 
Totals 36 43 43 41 
 505 
